JPS6187621A - Remedy for allergic rhinitis and allergic asthma - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

DETAILED DESCRIPTION OF THE INVENTION (a) Industrial application field The present invention is directed to allergic inflammation, allergic inflammation,
The present invention relates to therapeutic drugs, particularly drugs for treating allergic disease 1 and allergic asthma, which have no side effects and are regularly used as preventive drugs.

(b) R rice technology and problems allergic rhinitis and allergic asthma are caused by antigen-antibody reactions, such as histamine, serotonin, acetylcholine,
Keeping substances that cause allergic reactions such as kinine in close proximity, these substances are used to cause swelling of mucous membranes, edema, and secretion of glands.
This causes contraction of the choosymorrhoids (asthma E, 1), etc., and the respective symptoms appear.

Conventionally, antihistamine drugs have been used as therapeutic agents for this, for example, to block free histamine from binding to histamine receptors within tissue cells. Also used are steroid drugs, such as P-dermal hormone.

These anti-allergic drug treatments have rapid effects but are symptomatic without long-lasting effects, and all have side effects. Although non-steroidal drugs are also used, it is not possible to ignore the effects of 1.11.

Recently, prostaglandin derivatives have been proposed as therapeutic agents for allergic rhinitis and allergic asthma, but they tend to cause side effects such as fever after administration ( , is considered a problem.

(C) Structure of the Invention The present invention eliminates the problems of conventional therapeutic drugs for allergic rhinitis and allergic asthma, and is an allergy f!
1: The purpose is to provide therapeutic agents for rhinitis and allergic asthma, thereby achieving radical treatment for these chronic diseases.

The present invention is characterized in that the prostaglanone precursor fatty acid, nohomo-gamma-lylunic acid (DGLA), is produced from linoleic acid via gamma-linolenic acid, and from 7-linolenic acid to gamma-linolenic acid.
The present invention has reached the point where the process to form lyrinnic acid is significantly enhanced depending on the amount of dehydrogenase in the body.

That is, the present invention resides in a therapeutic agent for allergic rhinitis and allergic asthma that contains γ-lylunic acid.

According to the present invention, linoleic acid is used together with γ-linolenic acid.

In the present invention, γ-linolenic acid and 7-
Ruic acid cannot be produced in 5J+ objects, so it must be obtained from food, that is, it is necessary! 11
For 69-noleic acid, which is a fatty acid, sub-U+seed oil,
Although it is present in many plants such as cottonseed oil, sunflower seed oil, sesame oil, peanut oil, olive oil, and pepper oil, γ-lylunic acid is present only in evening primrose seed oil, evening primrose oil, etc. Oeno
Thera! e n n j G ), Oenothera Iamar
ckiana), and Efthera Holakeri (Oeno
therahoo, keri) as well as plants of the Prunusaceae, Sesame/Cullaceae family, such as Alkanna froeclini (Alkanna froeclini i).
), Scrophu-1
aria Brayana). Among these seed oils, evening primrose oil is especially known for its γ-
Linolenic acid contains about 6% of the total fatty acid, and linoleic acid contains about 72%, which is preferable as including the γ-linolenic acid of the present invention. It is also preferable for use with burrs. However, γ-linolenic acid may also be extracted and used (1+) For the treatment of allergic rhinitis and allergic asthma, the amount of γ-linolenic acid per day for adults is Acid!
)town! No:) 0 Town/('Yes, Tsukimi 1.1: Oil C about 11.10 *y or about 500η is used. I took the Tsukimi ry oil that looks far at this throw Ij, , j, t In some cases, IQ i:L's moonlight, r, and the unpleasant smell and resistance that exist in oil cannot be tolerated.

The second dose/amount is Tsukimi 1y Oil Throw for the treatment of arthritis! j-Q e.g. 2-20. 1 compared to g
The amount of Tsukimi is very small, and it is used not only as a health food but also as a prescribed diet. Since the intake amount of T oil is significantly smaller than that of T oil, it is possible to avoid, for example, the unpleasant odors of eructation and eructation that occur in these cases.

Furthermore, the present invention also provides 11 preventive treatments for allergic rhinitis and allergic asthma, and since it is desirable to take 1 liter every time, it is necessary to suppress the generation of unpleasant odors. It has the effect of reducing resistance by 70%.

The therapeutic agent for allergic inflammation and allergic asthma of the present invention can be used orally, enterally, parenterally, or locally in combination with an appropriate pharmaceutical carrier. Thus, for example, tablets,
Manufactured into capsules, oral liquid medicines, inhalation liquid medicines, powder pharmaceuticals, and za-lok, etc.

Hydrolyzed injection solutions of evening primrose oil may be prepared using fulpmin to solubilize the free acid. Further, it is preferable to mix tofu-7erol at a concentration of, for example, about 0.1% by weight in the pharmaceutical preparation to prevent oxidation.

The results of toxicity and pharmacology tests shown below demonstrate the antiallergic activity of the present invention.

Acute Toxicity Using 10 4-week-old IC'R male pines in one group, evening primrose oil was administered orally using the Litchfield-Wilfuchson method.
The acute toxicity was investigated and the LD50 was 5000η/
It was more than Lq.

Pharmacological test Sl) system male) was used for around 150 years, and a physiological saline administration group was established in contrast to the evening primrose oil administration group, and each I [
Oral administration was performed continuously for 2 weeks at a dose of lcc per mouse.

Two weeks after pre-administration, rats were treated with ovalbumin and treated with I.
s E antibody titers were superimposed. Feeling 11. Did you watch J] for two consecutive weeks? , T was thrown under the same conditions as above.

After the experiment nf, 11; kill, obtain serum, and use the method of
1', TacJ, '1 xind K, Okumur
aJ.

l m +n LJ II Ol + 06 10
fl 2 (1971)), the I' CA titer was 1/10 (1 times) in the January song compared to the control 4T in the Tsukimi t Nito Nage group, which was 1yEi!1.
It became clear that life was being suppressed.

Hereinafter, examples showing embodiments of the present invention will be described as examples, but the technical scope of the present invention is not limited by these examples in any way.

(D) Example Evening primrose oil used in this example was obtained by cold hexane extraction, and purified by deacidification, decolorization, and deodorization. T ) was performed, and the encapsulated product was used for experiments.

Example 1 RX oil was administered to patients with hay fever allergies.

Of the 25 cases of hay fever, 5 cases were non-throwing Lj as controls, and the remaining 9 cases.
One Tsukimi 1y oil capsule (combined γ-lylunic acid + 4.8y7) containing 250q of primrose oil was administered to 20 people every day for one month.

Of the 20 cases in this throwing group, 14 cases had relatively mild hay fever. In mild cases, in 10 out of 1 = i cases, the symptoms of itching and hyperemia of the ocular mucosa, itching and irritation in the nasal cavity, and excessive islet fluid were observed to be alleviated, and 4 of these cases had most of the symptoms. did not show.

However, in the remaining 6 out of 20 patients, although they were aware that their allergic rhinitis was alleviated, their symptoms gradually worsened, and they had no choice but to use anti-inflammatory drugs such as steroids.

Example 2 Each year, 20 patients who suffer from pollen allergy in the spring were given one 250-pound evening primrose oil capsule daily from February, two months before the onset of symptoms in April or May.

As a control, we found hay fever in 4 patients in the no-throwing group from April to May, but symptoms were significantly reduced in 12 out of 16 patients in the throwing + j group, and in the remaining 4 patients. Ta. According to this example, a preventive effect of "11" was also observed.

(,1,) Effects The therapeutic agent for allergic O inflammation and allergic asthma of the present invention has a major feature in that it exhibits not only a therapeutic effect on 1i(1i) but also a P protective effect. The main ingredient is γ-linolenic acid, an essential fatty acid, which must be ingested from the outside through food, etc., and although there are almost no rigid substances, it is an effective therapeutic and preventive drug. It is excellent as a

In addition, the therapeutic agent for allergic rhinitis and allergic asthma of the present invention has a low content of 5 to 5 Oq (Oq) for 1 dose of γ-Li/Si/acid for adults, and contains linoleic acid. Even if it is evening primrose oil, it costs 100 to 500
Since it is low in mg, for example, M? Even if you take it all the time for medical treatment and prevention of F, the dose is small and you may feel discomfort due to the unpleasant odor accompanying the impure ingredients of evening primrose oil when taking it. It has become easier to
It is very good for long clothes.

Furthermore, allergic rhinitis and allergic 1111”
-Regarding breath, most of it is of an AFP nature,
More and more R-uses are targeted at children, but as mentioned above, the small amount of A'L that is used means that, for example, even if evening primrose oil is encapsulated and administered, the size of the capsule can be made smaller. Furthermore, the number of capsules to be taken is small, clean and easy to take, and is excellent for continuing long-term treatment and prevention for children.

As the therapeutic agent for allergic rhinitis and allergic asthma of the present invention, for example, Tsukimi 1.1 oil, which contains sulfuric acid in addition to γ-linolenic acid, can be used. In this case, γ-linolenic acid is produced in the body from linoleic acid by the action of dehydrogenase in the body, so the amount of γ-linolenic acid can be increased by the coexisting lyric acid. Therefore, for example, even if this function is reduced due to regular alcohol use, etc., the supply of γ-lylunic acid continues, so the production of γ-lylunic acid tP [decreases]! +

As described below-1-, the present invention is directed to allele-'fJ:1. It makes possible a radical cure for allergic asthma.
〉There are things that need to be learned.

Representative person

Claims (2)

[Claims] (1) A therapeutic agent for allergic rhinitis and allergic asthma containing γ-linolenic acid. (2) The therapeutic agent for allergic rhinitis and allergic asthma according to claim 1, wherein the substance containing γ-linolenic acid is evening primrose oil.